Biosensor developer Nexense has raised equity funding in excess of $3 million from a group of private investors led by Chicago-based Emmes LLC.
Nexense CEO Arik Ariav said, "Nexense is at the final stage of product integration and customization for a number of its vital sign monitoring devices targeted for home use. This funding will enable us to move faster in adapting our technology to additional monitoring applications, and to accelerate our market entry."
Nexense's biosensor platform is based on a patented method of measuring parameters such as temperature, acceleration, pressure, distance, weight and any other physical entities. Unlike conventional sensors, Nexense Technology does not have a direct correlation between resolution and signal-to-noise ratio. This enables a higher dynamic range, as large as 24 bit by 1 meter resolution, in real time. Nexense states that it provides measurements that are 10,000 to 100,000 times better than existing technologies at a signal ratio of 190 db, while the best state of the art technologies can only deliver up to 120db.
Nexense can provide real-time monitoring of numerous physiological parameters in a completely non intrusive manner, including pulse rate with beat-to-beat variability, respiratory rate and characteristics, for example body movements, temperature, blood flow and densities.
The company has partnered with companies in the areas of health care, as well as automotive, aerospace and communications.
"Our investment will enable the company to grow faster, both domestically and internationally," said Emmes executive Arnold Thaler. "In particular, the company's biosensor platform will enable the development of non-intrusive devices for home health monitoring, a sector that is rapidly expanding."
Nexense has its business operations in the US and an R&D facility in Israel.
Published by Globes [online], Israel business news - www.globes.co.il - on Monday, January 31, 2005